墨西哥HNF1A p.E508K变异携带者对磺脲类药物反应未增强
研究招募96名参与者(46名变异携带者,50名年龄性别匹配的非携带者),评估墨西哥人HNF1A p.E508K变异与磺脲类药物敏感性的关联。结果显示携带p.E508K变异的糖尿病患者在格列吡嗪和二甲双胍联合口服葡萄糖负荷后胰岛素峰值和AUC均低于非携带者,结论为携带者胰岛素反应降低而非MODY3患者中所见的磺脲类药物敏感性增加。
要点
- 墨西哥HNF1A p.E508K变异携带者糖尿病患者的格列吡嗪刺激后胰岛素峰值低于非携带者糖尿病患者(P < 0.05)。
- 携带者口服葡萄糖负荷后胰岛素反应降低,合并糖尿病者在二甲双胍存在时胰岛素峰值和AUC均低于非携带者。
- 无糖尿病参与者中观察到类似但无显著差异的趋势。
核心结论
- HNF1A p.E508K变异携带者表现为胰岛素反应降低,而非MODY3患者中所见的磺脲类药物敏感性增加。
研究设计与样本
- 招募96名参与者(46名变异携带者,50名年龄和性别匹配的非携带者),采用先前验证的方案评估对格列吡嗪(单次2.5-5.0 mg剂量)、二甲双胍(四次500 mg剂量)和口服葡萄糖负荷的反应。
主要发现
- 携带p.E508K变异的糖尿病患者在格列吡嗪刺激下最大胰岛素峰值低于非携带者糖尿病患者(P < 0.05)。
- 携带者口服葡萄糖负荷后胰岛素反应低于非携带者。
- 在二甲双胍存在下进行口服葡萄糖耐量试验时,携带p.E508K变异的糖尿病患者最大胰岛素峰值及总胰岛素AUC和增量胰岛素AUC均低于非携带者糖尿病患者(P < 0.05)。
- 无2型糖尿病参与者中观察到类似但无显著差异的趋势。
关键数值与推荐
- 格列吡嗪剂量为2.5-5.0 mg单次给药;二甲双胍剂量为500 mg四次给药。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess whether an ethnic-specific variant (p.E508K) in the maturity-onset diabetes of the young (MODY) gene hepatocyte nuclear factor-1α (HNF1A) found in Mexicans is associated with higher sensitivity to sulfonylureas, as documented in patients with MODY3. RESEARCH DESIGN AND METHODS: We recruited 96 participants (46 variant carriers and 50 age- and sex-matched noncarriers). Response to glipizide (one 2.5-5.0-mg dose), metformin (four 500-mg doses), and an oral glucose challenge was evaluated using a previously validated protocol. Glucose and insulin levels and their areas under the curve (AUCs) were compared between groups. RESULTS: Carriers of the p.E508K variant had a lower maximum insulin peak during the glipizide challenge as compared with noncarriers with diabetes (P < 0.05). Also, carriers had a lower insulin response after the oral glucose challenge. Following an oral glucose tolerance test in the presence of metformin, carriers of the p.E508K variant with diabetes had a lower maximum insulin peak and total and incremental insulin AUC value as compared with noncarriers with diabetes (P < 0.05). A similar but nonsignificant trend was seen in participants without type 2 diabetes. CONCLUSIONS: Carriers of variant p.E508K in HNF1A have a reduced insulin response rather than the increased sensitivity to sulfonylureas seen in patients with MODY3.
引用
- Martagón AJ, Bello-Chavolla OY, Arellano-Campos O, et al. Mexican Carriers of the HNF1A p.E508K Variant Do Not Experience an Enhanced Response to Sulfonylureas. Diabetes Care. 2018. PMID: 29844095. doi:10.2337/dc18-0384
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。